Company

Carbiotix is an award winning pre-clinical stage therapeutics company leveraging low-cost gut health testing and microbiome modulators to unlock the potential of the gut microbiome to address a range of chronic and metabolic diseases.

Read More »

Gut Health Testing

Gut health testing

Carbiotix low-cost gut health test services are offered to consumers and companies as a means to cost effectively track gut health over time and overcome the natural variability associated with gut microbiome testing. The gut health tests serve as both a therapeutic discovery and diagnostic platform as well as assist with verifying and amplifying the efficacy of Carbiotix therapeutics.

View Services »

Microbiome Therapeutics

Microbiome Therapeutics

Carbiotix is developing a new generation of microbiome modulators based on proprietary second-generation soluble fibers, isolated bacterial strains and novel delivery mechanisms. This approach will allow Carbiotix to target a broad range of chronic and metabolic conditions by optimizing a person’s microbiome metabolic profile with high efficacy propriety therapeutic solutions.

View Therapies »

Track your gut health

Services

OneGut
OneGut™

The most reliable and cost effective consumer gut health test on the market.

Read more »
LinkGut
LinkGut™

A white label service for those interested in offering their own gut health test.

Read more »
StudyGut
StudyGut™

A reliable and cost effective testing service for gut health related clinical studies.

Read more »
Available worldwide

Gut health starts with fiber

Therapies

It is the belief of Carbiotix that activity within the gut microbiome is more important than the presence of specific bacteria species. As such, the company is focused on engineering microbiome modulators to restore and optimize gut microbiome metabolic processes and thereby obtain a desired therapeutic effect through an improved metabolic profile.

Microbiome modulater graph

Unlocking the potential of fiber

Investors

Carbiotix is a public pre-clinical stage therapeutics company leveraging low-cost gut health testing and microbiome modulators to unlock the potential of the gut microbiome to address a range of chronic and metabolic diseases.

Financial Calendar

Jan 01 - Dec 31, 2019

Current fiscal period


Nov 14, 2019

January - September 2019


Feb 12, 2020

Bokslutskommuniké för 2019


Full financial calendar »

Stock

Latest price: SEK
Updated at: Feb 20, 2020, 08:20